Equities analysts expect that RenovoRx, Inc. (NASDAQ:RNXT – Get Rating) will report earnings of ($0.25) per share for the current quarter, according to Zacks. Zero analysts have made estimates for RenovoRx’s earnings. The business is scheduled to report its next earnings results on Monday, January 1st. On average, analysts expect that RenovoRx will report full […]
RenovoRx (NASDAQ:RNXT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California. “ RenovoRx […]
RenovoRx Inc (NASDAQ:RNXT – Get Rating) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 33,900 shares, a decrease of 58.2% from the February 28th total of 81,100 shares. Approximately 0.6% of the shares of the company are sold short. Based on an […]
Analysts predict that RenovoRx Inc (NASDAQ:RNXT – Get Rating) will post earnings per share of ($0.18) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for RenovoRx’s earnings. The firm is scheduled to issue its next earnings results on Monday, January 1st. On average, analysts expect that RenovoRx will report full-year […]
/PRNewswire/ RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, today announced the pricing of its underwritten initial.